Another Deal for AlzeCure Pharma
July 30, 2026
Welcome to Greg’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
Due to the time required for research and writing, Greg’s Alzheimer’s Research Report is a subscription-only publication. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
SUMMARY
QuantumCell, a Danish tech-enabled biotech company, has acquired global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. The deal is valued at approximately 2.2 billion US dollars.
